U
FOMX

UBS’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

UBS’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$13K Buy
+2,405
New +$13.8K ﹤0.01% 8564

Other funds holding FOMX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS's FOMX Position: Q3 2014 in Review

UBS opened a new position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2014: 2,405 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #8564 among its holdings.

19 funds tracked by Wall St. Rank hold FOMX as of Q3 2014.

  • UBS held 2,405 shares of Foamix Pharmaceuticals Ltd. Ordinary Shares worth $13K as of Q3 2014.
  • Foamix Pharmaceuticals Ltd. Ordinary Shares was a new UBS position in Q3 2014.
  • Foamix Pharmaceuticals Ltd. Ordinary Shares made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8564 holding.
  • 19 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.